Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to a durable effect for a drug ...

The FDA has denied Lykos Therapeutics' marketing application for its post-traumatic stress disorder (PTSD) therapy based on MDMA, also known as ecstasy, in a setback for the emerging psychedelic ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities ...

Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure. The European Commission revoked the conditional ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Therapeutics candidate with a ...

Good Clinical Practice (GCP), the bedrock of ethical and high-quality clinical research, guides operations among sponsor companies, contract research organisations (CROs), investigator sites, and ...

The UK is squandering the vast resource of NHS patient data because too many obstacles are being placed in front of researchers trying to tap into it – holding back medical advances. That is the ...

The pivotal shift in biopharma priorities is steering towards enhancing sustainability measures for drug development. Continuous processing keeps the industry grounded in reaching propelled ESG ...